Login / Signup

A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction.

Robert A KlonerPaul GogginIrwin GoldsteinGeoffrey HackettMichael G KirbyIan OsterlohJohn D ParkerRichard Sadovsky
Published in: Journal of cardiovascular pharmacology and therapeutics (2018)
This literature review determined that the use of phosphodiesterase type 5 inhibitors with nitrates is a contraindication, with the duration between the last dose of phosphodiesterase inhibitor and nitrate use generally varying between short- and long-acting phosphodiesterase type 5 formulations. Patients receiving nitrates who wish to use phosphodiesterase type 5 inhibitors should be educated regarding the interaction and should be evaluated to determine whether nitrate treatment can be discontinued. Further research is needed to determine how soon phosphodiesterase type 5 inhibitors can be restarted after a patient has taken a nitrate and the effect of high and low phosphodiesterase type 5 inhibitor doses on the interaction effect.
Keyphrases
  • nitric oxide
  • drinking water
  • case report
  • replacement therapy